Kymera Therapeutics (KYMR) Capital Expenditures (2019 - 2026)
Kymera Therapeutics (KYMR) reported Capital Expenditures of $434000.0 for Q1 2026, down 7.07% year-over-year from $467000.0 in Q1 2025, and up 309.43% quarter-over-quarter from $106000.0 in Q4 2025.
Kymera Therapeutics (KYMR) Capital Expenditures (2019 - 2026) Analysis & Trends
Kymera Therapeutics (KYMR) has 8 years of Capital Expenditures data on file, last reported at $434000.0 in Q1 2026.
- Capital Expenditures for Q1 2026 came in at $434000.0, down 7.07% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.4 million (down 76.01% YoY), and the FY2025 annual result was $1.4 million, down 88.71% from the prior year.
- Capital Expenditures grew to $434000.0 in Q1 2026 per KYMR's latest filing, from $106000.0 in the prior quarter.
- Over five years, Capital Expenditures peaked at $11.6 million in Q4 2023 and troughed at -$189000.0 in Q3 2024.
- A 5-year average of $3.1 million and a median of $735000.0 in 2022 frame the typical range for Capital Expenditures.
- The sharpest annual moves came in 2023 and 2024: Capital Expenditures soared 3016.62% in 2023, then tumbled 102.34% in 2024.
- A 5-year view of Capital Expenditures shows it stood at $373000.0 in 2022, then soared by 3016.62% to $11.6 million in 2023, then slumped by 91.95% to $936000.0 in 2024, then slumped by 88.68% to $106000.0 in 2025, then jumped by 309.43% to $434000.0 in 2026.
- Business Quant data shows KYMR's Capital Expenditures at $434000.0 in Q1 2026, $106000.0 in Q4 2025, and $181000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 133.40 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -63,220.27 |
| 10 | Kymera Therapeutics | 8.84 Bn | 8.19 Bn | - | 434,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 434,000.00 |
| Mar 31, 2026 | 434,000.00 |
| Dec 31, 2025 | 106,000.00 |
| Dec 31, 2025 | 106,000.00 |
| Sep 30, 2025 | 181,000.00 |
| Sep 30, 2025 | 181,000.00 |
| Jun 30, 2025 | 695,000.00 |
| Jun 30, 2025 | 695,000.00 |
| Mar 31, 2025 | 467,000.00 |
| Mar 31, 2025 | 467,000.00 |
| Dec 31, 2024 | 936,000.00 |
| Dec 31, 2024 | 936,000.00 |
| Sep 30, 2024 | -189,000.00 |
| Sep 30, 2024 | -189,000.00 |
| Jun 30, 2024 | 4.69 Mn |
| Jun 30, 2024 | 4.69 Mn |
| Mar 31, 2024 | 7.40 Mn |
| Mar 31, 2024 | 7.40 Mn |
| Dec 31, 2023 | 11.63 Mn |
| Dec 31, 2023 | 11.63 Mn |